MORF Key Statistics, Chart & Performance
The current stock price of MORF is 56.99 USD. In the past month the price increased by 1.19%. In the past year, price increased by 5.11%.
MORF Latest News, Press Relases and Analysis
MORF Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.07 | 401.99B | ||
| AMGN | AMGEN INC | 14.87 | 175.17B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.25 | 115.62B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.72 | 79.10B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 767.65 | 51.72B | ||
| INSM | INSMED INC | N/A | 42.00B | ||
| NTRA | NATERA INC | N/A | 31.52B | ||
| BIIB | BIOGEN INC | 10.5 | 25.78B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.96 | 21.54B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B | ||
| INCY | INCYTE CORP | 15.36 | 19.37B |
Related stock screener links
About MORF
Company Profile
Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2019-06-27. The firm is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The company has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Company Info
MORPHIC HOLDING INC
35 Gatehouse Drive A2
Waltham MASSACHUSETTS 02451 US
CEO: Praveen P. Tipirneni
Employees: 124
Phone: 17819960955
MORPHIC HOLDING INC / MORF FAQ
Can you describe the business of MORPHIC HOLDING INC?
Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 124 full-time employees. The company went IPO on 2019-06-27. The firm is engaged in discovering and developing a pipeline of potentially oral small molecule integrin therapeutics for the treatment of serious chronic diseases, including autoimmune, cardiovascular and metabolic diseases, fibrosis and cancer. The Company’s Morphic integrin technology platform (MInT Platform) helps to develop product candidates designed to achieve the potency, high selectivity and pharmaceutical properties required for oral administration. The firm is advancing its pipeline, including its lead product candidate, MORF-057, an orally administered a4b7-specific integrin inhibitor affecting inflammation, into clinical development for the treatment of inflammatory bowel disease (IBD). The company has also developed avb6-specific integrin inhibitors for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and additional indications.
Can you provide the latest stock price for MORPHIC HOLDING INC?
The current stock price of MORF is 56.99 USD. The price increased by 0.04% in the last trading session.
Does MORPHIC HOLDING INC pay dividends?
MORF does not pay a dividend.
What is the ChartMill technical and fundamental rating of MORF stock?
MORF has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Where is MORPHIC HOLDING INC (MORF) stock traded?
MORF stock is listed on the Nasdaq exchange.
How is the market expecting MORF stock to perform?
15 analysts have analysed MORF and the average price target is 59.6 USD. This implies a price increase of 4.57% is expected in the next year compared to the current price of 56.99.
Is MORPHIC HOLDING INC (MORF) expected to grow?
The Revenue of MORPHIC HOLDING INC (MORF) is expected to decline by -50.42% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
MORF Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to MORF. When comparing the yearly performance of all stocks, MORF is one of the better performing stocks in the market, outperforming 94.75% of all stocks.
MORF Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MORF. MORF has a great financial health rating, but its profitability evaluates not so good.
MORF Financial Highlights
Over the last trailing twelve months MORF reported a non-GAAP Earnings per Share(EPS) of -3.75. The EPS decreased by -15.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.83% | ||
| ROE | -29.08% | ||
| Debt/Equity | 0 |
MORF Forecast & Estimates
15 analysts have analysed MORF and the average price target is 59.6 USD. This implies a price increase of 4.57% is expected in the next year compared to the current price of 56.99.
For the next year, analysts expect an EPS growth of -16.05% and a revenue growth -50.42% for MORF